DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (D. ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at the Liver Meeting® 2025. The oral presentation will feature new PBGENE-HBV data from the first two cohorts of the Phase 1 ELIMINATE-B Trial. The Liver Meeting 2025, which is th. ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the publication of a peer-reviewed manuscript titled "High- Efficiency Homology-Directed Insertion into the Genome using the Engineered Homing Endonuclease ARCUS†in the journal Nucleic Acids Research. This publication demonstrates a wide variety of g. ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of its first U.S. clinical trial site to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The newly activated site at Massachusetts General Hospital in Boston, Massachusetts, is now actively recruiting patients. ". ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. "We look forward to sharing the latest preclinical data for PBGENE-DMD at the upcoming. ...

核心观点 - 公司公布其基于ARCUS®平台开发的PBGENE-HBV在慢性乙型肝炎患者中的1期临床试验数据 [1] 产品与平台 - 公司采用专有ARCUS®平台开发体内基因编辑疗法 [1] - 主要针对未满足高需求疾病领域 [1] 临床试验 - 临床数据来自ELIMINATE-B试验的1期研究 [1] - 数据在国际乙型肝炎消除联盟（ICE-HBV）于柏林举办的"HBV治愈研讨会"上公布 [1]